Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

October 16, 2025 Report

US State Regulatory Spotlight on Healthcare Transactions — Reflections From 2025

Medical professional walking down hospital corridor.

September 25, 2025 Client Alert

Bipartisan Bill Aims to Expand Sunshine Act Reporting for Manufacturers

Multi-colored tablet and capsule pills lying on a white surface.

September 24, 2025 Client Alert

FDA Begins Crackdown on Direct-to-Consumer Pharmaceutical Advertising

Digitally rendered image electrocardiograph line.

July 30, 2025 Webcast

Healthcare Implications of the One Big Beautiful Bill: What You Need to Know

LIF_Reeves-1600x1080-THUMB-LightBlue_V01

July 7, 2025 Video

Latham in Focus: Healthcare & Life Sciences Competition Considerations

Digitally rendered gel capsule filled with multicolor spheres.

November 3, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 58

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law.

November 3, 2025 Podcast

Episode 104 — Drug Pricing and Market Access: Deep Dive on the FDA Commissioner’s National Priority Voucher Program Awards

FDA just announced nine awards under the new CNPV program, based in part on drug pricing and onshoring of manufacturing. We review the awards in detail, consider possible agency rationale, and investigate broader implications on pharmaceutical pricing, launch strategies, and market transparency.

October 29, 2025 Client Alert

New German Authority Guidelines Set Gold Standard for Data Transfers in Medical Research Collaborations

October 20, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 57

October 16, 2025 Report

US State Regulatory Spotlight on Healthcare Transactions — Reflections From 2025

October 02, 2025

Episode 103 — Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

The largest drug pricing conference of the year just concluded in Chicago. Join the Latham team to discuss key themes and highlights, including most favored nation pricing considerations, bona fide service fee changes, and 340B program developments.

July 30, 2025

Healthcare Implications of the One Big Beautiful Bill: What You Need to Know

Members of Latham’s Healthcare & Life Sciences Practice discuss impacts of the OBBB’s healthcare policy provisions. MCLE credit offered.

June 24, 2025

Episode 99 — Drug Pricing: Takeaways From the Philadelphia Pricing and Contracting USA Conference

Join the Latham team and Allan Thoen from Sandoz to hear about the key themes and highlights from one of the year’s significant drug pricing conferences.

Abstract background of wires and glowing particles

June 26, 2025

Access Denied — Navigating the New DOJ Data Security Program With Confidence

Latham’s team of lawyers focusing on data security and national security examine DOJ’s DSP and its potential implications for companies. MCLE credit offered.

June 06, 2025

Episode 98 — Drug Pricing: Takeaways From the MDMA Annual Meeting

One of the country’s largest medical innovation and policy conferences recently concluded in Washington, D.C. Join the Latham team to discuss takeaways from the meeting, including regulatory changes and compliance hot topics.

Shiny transparent capsule filled with colorful spheres

May 02, 2025

Episode 97 — Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps With Grassley-Led Legislation

On April 15, President Trump signed an executive order addressing prescription drug prices. The Latham team analyzes how the EO might impact FDA and dovetails with five bills recently (re-)introduced in the Senate.

March 12, 2025

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

The Department of Government Efficiency, Trump executive orders, and a recent Office of Management and Budget memorandum are making drastic changes at FDA. The Latham team discusses the potential impacts on FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

February 25, 2025

Episode 94 — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

One of the country’s largest healthcare conferences recently concluded in San Francisco. Join the Latham team to discuss takeaways from the conference, including AI innovation and increased dealmaking activity, and consider the policy outlook under the new Trump administration.

Drop of clear blue liquid from droper droping to test tube in laboratory with bright color blur background.

December 30, 2024

Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

Latham speaks with BridgeBio’s CEO/founder and CFO about BBIO’s growth story — its past, present, and future.

December 17, 2024

Episode 88 — Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Explore recent FDA enforcement trends and the agency’s current focus, and consider potential priorities under the incoming Trump Administration.

November 26, 2024

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.

October 21, 2024

Episode 86 — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit

One of the year’s major drug pricing conferences just concluded in Chicago. Join the Latham team to discuss takeaways from the conference, including highlights from remarks by government speakers.

Front View of US Supreme Court in Washington DC, including the inscription Equal Justine Under Law

September 19, 2024

The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries

Latham lawyers discuss the implications of the US Supreme Court decision in Loper Bright. MCLE credit offered.

September 19, 2024

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.

August 19, 2024

Episode 83 — Drug Pricing: How Are Payers Responding to the IRA?

Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.

Our Archive

November 7, 2025 Our Work

Latham & Watkins Advises 4D Molecular Therapeutics on US$100 Million Offering of Common Stock and Pre-Funded Warrants

Multidisciplinary team represents the late-stage biotechnology company in the transaction.

Close-up of medical professional wearing blue gloves pipetting liquid into a vial.

November 7, 2025 Our Work

Latham & Watkins Advises on Halozyme Therapeutics’ Convertible Senior Notes Offerings Totaling US$1.3 Billion

Firm represents the initial purchasers in the offerings by the biopharmaceutical company.

November 6, 2025 Our Work

Latham & Watkins Advises Precision Concepts International in Acquisition of Comar

November 5, 2025 Our Work

Latham & Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech to Form AtaiBeckley

November 4, 2025 Our Work

Latham & Watkins Advises Evoke Pharma on Acquisition by QOL Medical

November 7, 2025 Recognition

Gwyn Williams: 2025 Go-To Lawyer for Commercial/Consumer Law

Partner Gwyn Williams was recognized for her experience and leadership in handling complex products liability, mass tort, and consumer class action cases.

October 15, 2025 Recognition

Distinguished Leader: David Tolley

Chair of Latham & Watkins' Boston Litigation & Trial Department honored as a winner by the New England Legal Awards.

Soft focus bokeh light effects over a rippled, blue water background in the pool.

September 22, 2025 Recognition

Litigators of the Week Winner: Truce With Generic Makers Over Rinvoq Sends AbbVie Share Price to New High

A Latham team led by David Frazier won the “Litigators of the Week” competition, alongside co-counsel at Covington, for their outstanding representation of AbbVie in securing the latest of five patent litigation settlements with generic makers that are set to protect its blockbuster immunology drug Rinvoq until 2037.